BACKGROUND: The third leading cause of cardiovascular-associated death, venous thromboembolism (VTE), represents a significant health care and economic burden. Although the burden of a one-time VTE event has been assessed, there are limited data regarding the burden of VTE recurrence.
RESULTS: Among the commercially insured population, 29,275 patients were diagnosed with VTE and received anticoagulant therapy. A recurrence of VTE associated with a hospitalization or ER visit occurred within 12 months of the index VTE in 15.4% of patients with a mean time to recurrence of 74.1 days. Among the Medicare insured population (n = 14,509), 11.4% of patients experienced another VTE with a mean time to recurrence of 115.6 days. A consistent predictor of VTE recurrence across both populations was greater comorbidity as indicated by Charlson Comorbidity Index scores. Among commercially insured VTE patients, total payments for health care resource utilization for all causes, including inpatient, outpatient medical services, and outpatient pharmacy use were higher for patients with a recurrent VTE relative to those without a recurrent VTE ($82,110 [$106,918] vs. $36,918 [$54,852], P < 0.001). The primary driver for the higher health care payments was greater use of inpatient care. Total payments for VTE-related resource use was also greater for patients with a VTE recurrence ($38,591 [$51,479] vs. $15,123 [$22,186] , P < 0.001) with the majority (62.9%) attributed to care that took place within 30 days of the index VTE. After adjustment for key patient characteristics, VTE recurrence was associated with 2.2-fold and 3.0-fold higher post-index health care payments for all causes and for VTE-related claims, respectively. Similar results were observed for the Medicare population.
R E S E A R C H
• The third leading cause of cardiovascular-associated death, venous thromboembolism (VTE), represents a significant health care and economic burden.
• The annual average number of hospitalizations attributed to VTE is more than 500,000.
• Average total annual hospitalization costs (1998) (1999) (2000) (2001) (2002) (2003) (2004) for VTE patients have been estimated to range between $7,594 and $27,909, depending on the type of event and whether it was a primary or secondary diagnosis.
• Among hospitalized VTE patients, direct medical costs for VTE per patient per year are substantial and result not only from the initial VTE hospitalization event, but also from a high rate of hospital readmission for a subsequent VTE (5.3%-14.3%).
What is already known about this subject
• Even with anticoagulant treatment, the incidence of VTE recurrence associated with a hospitalization or emergency room visit ranged from 11.4% to 15.4%, with the majority of recurrences occurring within 30 days of the initial VTE.
• The likelihood of VTE recurrence appears to be most strongly related to comorbidities.
• Among both commercially and Medicare insured VTE patients, total payments for VTE-related health care resource utilization, including inpatient, outpatient medical services, and outpatient pharmacy use, are 3.0-fold and 3.4-fold higher, respectively, for patients with a recurrence of VTE relative to those without a recurrent VTE.
• The primary driver for the higher health care costs is a greater use of inpatient care.
• Reducing VTE recurrence is critical to lessen the health care and economic burdens of VTE.
and prescription drug services for millions of beneficiaries residing in multiple states across the United States. Data from individual patients are integrated from all providers of care, maintaining all health care utilization and cost connections at the patient level. The MarketScan Medicare Supplemental database contains the Medicare covered, employer-paid, and any out-of-pocket portions paid for the health care encounter. In compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the databases consist of fully de-identified data sets, with synthetic identifiers applied to patient-level and provider-level data to protect the identities of both the patients and data contributors.
Study Population
Patients who had at least 1 inpatient claim with a primary or secondary VTE diagnosis or 2 outpatient claims (including emergency room (ER) visit) on 2 separate dates for VTE diagnosis as identified by . The ICD-9-CM code of 415.1 was used to identify patients who had a PE. The first VTE diagnosis to occur during the index VTE identification period was defined as the index VTE event, and the type of VTE (i.e., DVT, PE, or DVT/PE) was determined on the first day of the VTE diagnosis. Two outpatient claims were required to maximize the likelihood that a medical visit associated with VTE treatment did occur and minimize the risk of misidentifying an outpatient visit with a "rule-out" VTE diagnosis as an index event. To further increase the likelihood that the identified VTE diagnoses were for VTE events, all VTE patients were required to have evidence of VTE pharmacological treatment, defined as treatment with unfractionated heparin (UFH), LMWH, warfarin, or fondaparinux for a duration of ≥ 30 days and initiated within 30 days of the index VTE event. All patients within the study populations were required to be ≥ 18 years at the index VTE event and have 12 months of continuous medical and prescription benefit coverage prior to (baseline period) and after the index VTE event (follow-up period).
VTE Recurrence Definition
During the follow-up period, recurrence of VTE was evaluated for the commercially and Medicare insured populations. A recurrence of VTE was defined as having a hospital admission or ER visit identified by medical claims associated with a primary or secondary diagnosis of DVT and/or PE that occurred more than 2 days after the index VTE event (ICD-9-CM codes as previously mentioned). The 2-day period was used to rule out hospital admissions related to treatment of the index V enous thromboembolism (VTE) is a coagulation disorder that predisposes individuals to clot formation in the venous system, primarily in the veins of legs, called deep vein thrombosis (DVT). When a clot breaks free, it can travel to the lungs causing pulmonary embolism (PE), a sequelae of VTE that is directly associated with 5% to 10% of all in-hospital deaths. [1] [2] [3] The incidence of VTE increases with age with the Centers for Disease Control and Prevention reporting average annual rates of VTE ranging from 60 per 100,000 population for persons aged 18-39 years to 1,134 per 100,000 for persons aged ≥ 80 years. 4 Mahan et al. (2012) estimated that, in 2011 U.S. dollars, the annual cost of VTE ranges between $13.5 and $27.2 billion. 5 The substantial burden to the health care system and the high frequency of preventable cases have prompted the Surgeon General and the U.S. Department of Health and Human Services (Partnership for Patients) to elicit a call to action focused on reversing the projected trends of VTE. 6, 7 The treatment goals of VTE therapy are to stop clot propagation and to prevent thrombus recurrence and PE. 8 The American College of Chest Physicians recommends initial treatment for DVT or PE with parenteral low-molecular-weight heparin (LMWH) or anticoagulation with rivaroxaban and anticoagulation therapy (such as a vitamin K antagonist, LMWH, rivaroxaban, or dabigatran) for 3 months or longer depending on bleeding risk and whether the event was provoked, unprovoked, or associated with active cancer. 9 The health care and economic burdens of VTE are not only related to diagnosis and treatment of the initial event, but also to VTE recurrence. [10] [11] [12] Spyropoulos and Lin (2007) reported that hospital readmission rates of hospitalized VTE patients were between 5.3% and 14.3% by 1 year. 10 It is important to better understand the overall health care and economic burdens of recurrent VTE among both inpatient-and outpatienttreated VTE patients and to define populations at high risk for VTE recurrence in order to potentially improve the quality of care for VTE patients. 6, 7 To that end, this study's purpose was to evaluate the rate and predictors of VTE recurrences among both inpatient-and outpatient-treated VTE patients and determine the incremental burden of health care resource utilization and costs among patients with VTE recurrence who have commercial or Medicare insurance coverage in the United States. VTE event. For both the commercially and Medicare insured populations, patients were grouped into one of 2 cohorts; one composed of patients without a recurrent VTE during the 12-month follow-up period and the second composed of patients who experienced a VTE recurrence during the followup period. The time to first recurrent VTE for patients having been identified as having a recurrence was summarized.
Baseline Demographics and Clinical Characteristics
Patient demographics consisting of age, gender, and U.S. region of residence along with type of health plan were collected. Clinical characteristics consisting of index VTE type (i.e., DVT only, PE only, DVT/PE), setting of initial care (inpatient vs. outpatient), Deyo-Charlson Comorbidity Index (CCI), comorbidities, and Elixhauser Comorbidity Index (EI) were assessed based on data collected during the 12 months prior to the index event. History of hospitalization and/or surgery 30 days prior to the initial VTE were determined for all patients within the commercially and Medicare insured populations. The CCI is a widely used measurement that is predictive of the likelihood of 1-year and 10-year mortality based on the presence or absence of 19 comorbid conditions and their associated assigned weights. 13 The more recently developed EI, 14 a comorbidity index based on the presence or absence of 30 comorbid conditions, was also measured for each patient within the commercially and Medicare insured populations.
General Statistical Analyses
Descriptive statistics were used to summarize and compare the demographic and clinical characteristics of the study cohorts within the commercially and Medicare insured populations. Means, standard deviations (SD), and medians were reported for continuous data, and counts and percentages were reported for categorical data. For comparisons of health care utilization and associated costs between patients with and without recurrent VTE, t-tests and chi-square tests were used for continuous and categorical variables, respectively. A P value of 0.05 was used to determine statistical significance. All statistical analyses were carried out using SAS 9.2 (Cary, NC).
Patient Characteristics that Impact VTE Recurrence
A Cox proportional hazards model, in which the time to VTE recurrence was the dependent variable, was conducted. Predictor covariates included age, gender, VTE type, setting of VTE diagnosis (inpatient or outpatient), CCI score, and U.S. region of residence.
Comparison of Health Care Resource Utilization and Payments at the Unadjusted Level: Patients with VTE Recurrence Versus Patients Without VTE Recurrence
Hospitalizations, including total length of stay (LOS), claims for outpatient medical services (all outpatient medical services and just those for ER visits), and outpatient prescription claims were evaluated for each patient in the study populations during a 30-day period following the index VTE event and for the entire 12-month follow-up period. Inpatient, outpatient medical services, and outpatient pharmacy resource utilization categories were grouped into all-cause (i.e., health care use for any reason) and VTE-related, which included all claims associated with a diagnosis of VTE. VTE-related outpatient pharmacy use consisted of prescribed anticoagulant use. All cost values in the study represent the health care payment amount. The health care payments made by health plans and the overall total reimbursed payments from health plans, patients and/or other third-party payers to the hospital for covered services provided during an admission were measured and reported. Health care resource utilization and associated costs were then compared among the study cohorts of patients with and without VTE recurrence. Results were reported separately for the commercially and Medicare insured populations.
Comparison of Adjusted Total Health Care Payments: Patients with VTE Recurrence Versus Patients Without VTE Recurrence
Generalized linear models with log transformation for cost data and gamma distribution as the link function were used to evaluate the impact of VTE recurrence on total payments, while controlling for key patient characteristics. Payments included those for health care resource utilization for any reason and those that were VTE-related. Absolute cost differences and cost ratios of total payments within 30 days and 12 months post-index VTE event were reported. Covariates used in the regression models were age, gender, VTE type, setting of initial VTE diagnosis (inpatient or outpatient), CCI score, and U.S. region of residence. We additionally carried out a sensitivity multivariable regression analysis in which additional covariates were added. These additional covariates were health plan types and comorbidities including cancer, congestive heart failure, chronic obstructive pulmonary disease/pulmonary diseases, severe infectious diseases, stroke/transient ischemic attack, acute coronary syndrome, hypertension, and diabetes.
■■ Results

Study Population
Among the commercially insured, 29,275 patients with an index VTE event were identified during the study selection period ( Figure 1 ). Among this study population, the recurrent VTE cohort consisted of 4,498 (15.4%) patients. The mean time to VTE recurrence was 74.1 days in this cohort. Among the Medicare insured, 14,509 patients with an initial VTE event were identified during the study selection period (Figure 1 ). The recurrent VTE cohort within this Medicare population consisted of 1,655 (11.4%) patients. The mean time to VTE recurrence was 115.6 days in this cohort.
Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective Baseline Demographics and Clinical Characteristics
Baseline demographics for the commercially and Medicare insured populations are presented in Table 1 . For the commercially insured population, the mean age was slightly higher for patients without a recurrent VTE (48.5 vs. 49.9 years, P < 0.001). The VTE recurrence cohort had a lower proportion of male patients than the cohort without VTE recurrence (48.1% vs. 51.5%, P < 0.001). For the Medicare insured population, mean ages (77.0 vs. 76.8 years, P = 0.307) and proportion of male patients were similar (45.1% vs. 46.2%, P = 0.370) for patients with and without VTE recurrence.
Baseline clinical characteristics for the commercially and Medicare insured populations are presented in Table 2 . Among the commercially insured population, DVT was the most common index VTE event type for patients with and without recurrent VTE (~59% for both cohorts), followed by PE only (~25%), and DVT/PE (15%-16%). The majority of index VTE events were treated in the inpatient setting (58% with recurrent VTE and 60% without recurrent VTE). Mean CCI (1.5 vs. 1.2, P < 0.001) and EI (2.7 vs. 2.4, P < 0.001) scores at baseline were greater for patients with VTE recurrence in comparison with patients without VTE recurrence. The proportion of patients with a hospitalization 30 days prior to the index VTE event was higher for patients with a VTE recurrence (14.5% vs. 11.8%, P < 0.001). Among the commercially insured population with recurrent VTE, significantly more patients had comorbidities of severe infectious diseases (29.3% vs. 24.7%, P < 0.001), cancer (17.5% vs. 13.3%, P < 0.001), chronic obstructive pulmonary disease/pulmonary diseases (15.7% vs. 13.9%, P = 0.001), and congestive heart failure (5.1% vs. 4.1%, P = 0.003).
Clinical characteristics of the index VTE event among the Medicare insured population were similar to the commercially insured population. DVT was the most frequent index VTE event type with a greater proportion of patients with recurrent VTE having this event type than patients without recurrent VTE (63.0% vs. 56.3%, P < 0.001). There were also fewer patients with an index PE event in the recurrent VTE cohort than the no recurrent VTE cohort (24.2% vs. 30.0%, P < 0.001). A lower proportion of patients who had a VTE recurrence were treated in the inpatient setting for their index VTE event in comparison with patients who did not have a recurrent VTE (51.4% vs. 58.6%, P < 0.001). Mean CCI (2.6 vs. 2.3, P < 0.001) and EI (3.9 vs. 3.6, P < 0.001) scores at baseline were greater for patients with VTE recurrence versus those without a recurrence. Among the Medicare insured population with recurrent VTE, significantly more patients had severe infectious diseases (36.4% vs. 31.3%, P < 0.001), cancer (32.8% vs. 28.6%, P = 0.001), and chronic obstructive pulmonary disease/ pulmonary diseases (27.5% vs. 24.7%, P = 0.013).
Outpatient Anticoagulant Use Among Study Populations
Inpatient use of anticoagulation therapy could not be evaluated because the data are not captured in the MarketScan databases. In the outpatient setting, the vast majority of commercially insured patients received warfarin for their index VTE events After exclusion of patients < 18 years of age n = 88,007
After exclusion of patients without anticoagulant treatment n = 29,275
After exclusion of patients without anticoagulant treatment n = 14,509
Patients with recurrent VTE during 12-month follow-up period n = 4,498
Patients without recurrent VTE during 12-month follow-up period n = 24,777
Patients with recurrent VTE during 12-month follow-up period n = 1,655
Patients without recurrent VTE during 12-month follow-up period n = 12,854
FIGURE 1
Flowchart of the Selection of Study Populations
Rx = prescription; VTE = venous thromboembolism.
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(96.2% of patients with VTE recurrence and 97.5% of patients without VTE recurrence). Most patients were also treated with an LMWH (70.5% of patients with VTE recurrence and 62.5% of patients without VTE recurrence). In the outpatient setting, the majority of Medicare insured patients were also treated with warfarin (97%-98%) for their index VTE events. Figure 2a presents the cumulative 12-month incidence of VTE recurrence among commercially insured patients by index event type. Among commercially insured patients who experienced a VTE recurrence, DVT was the most common recurrent event (experienced by 58.8% of patients, with a mean time to recurrence of 70.5 days) followed by PE (experienced by 24.8% of patients, with a mean time to recurrence of 76.4 days). A combined DVT/PE type of recurrence was identified in 16.4% of patients experiencing a recurrent event with a mean time to recurrence of 83.5 days. Among patients with VTE recurrences, the majority of recurrences occurred within the first month after the index VTE, with 58.3% of such recurrences occurring within the first month among VTE recurrence patients who had DVT as their index event, 57.2% of such recurrences occurring among VTE recurrence patients who had PE as their index event, and 51.4% of such recurrences occurring among VTE recurrence patients who had DVT/PE as their index event (see Figure 3a) . Figure 2b presents the cumulative 12-month incidence of VTE recurrence among Medicare insured patients within 1 year of the index VTE. Similar to results of commercially insured patients, the majority of Medicare insured patients experiencing a recurrence had a DVT (63.0%) with a mean time to recurrence of 110.3 days. PE (24.2%) was the second most frequent type of recurrence with a mean time to recurrence of 116. 4 Incremental Health Care Resource Utilization and Economic Burden of Venous Thromboembolism Recurrence from a U.S. Payer Perspective such that versus a score of 0, a score of 1-2 had an HR of 1.2 (P < 0.001), a score of 3-4 had an HR of 1.5 (P < 0.001), and a score of ≥ 5 had an HR of 1.8 (P < 0.001). U.S. region of residence did not impact VTE recurrence.
Incidence of Specific VTE Events and Time to Recurrence
Among Medicare insured patients with a VTE, age and gender did not affect the likelihood of VTE recurrence. Patients who had an index PE only versus those who had an index DVT only had a lower HR for VTE recurrence (HR: 0.8, P < 0.001). A greater CCI score (> 2) was associated with a greater risk for VTE recurrence, such that versus a score of 0, a score of 3-4 had an HR of 1.2 (P = 0.024), and a score of ≥ 5 had an HR of 1.5 (P < 0.001). Additionally, for the Medicare population, the U.S. region where care took place might also affect the probability of VTE recurrence.
Comparison of Health Care Resource Utilization and Associated Payments: Patients with VTE Recurrence Versus Patients without VTE Recurrence
During the 12-month follow-up period, commercially insured patients with a VTE recurrence associated with a hospitalization or ER visit had higher all-cause and VTE-related health each specific type of VTE recurrent event were greater than 3 months. However, 27%-38% of patients who had a recurrent VTE event experienced it within the first month after their index event (DVT only: 37.1%, PE only: 38.2%, DVT/ PE: 27.0%, Figure 3b) . The proportions of patients who experienced each specific type of recurrent VTE were between 8% and 9% within 3 months, between 4% and 6% at 6 months, and between 3% and 5% within 12 months.
Predictors of VTE Recurrence
The relationship between VTE recurrence and certain patient characteristics, treatment setting, and demographics are presented in Table 3 . Among commercially insured VTE patients, younger age, female gender, and outpatient treatment of index VTE increased the risk of VTE recurrence (lower age in years vs. each incremental year hazard ratio (HR): 0.99, P < 0.001; female vs. male HR: 1.1, P = 0.007; inpatient vs. outpatient setting HR: 0.9, P < 0.001). Patients who had an index DVT/ PE versus those who had an index DVT only had a greater HR for VTE recurrence (HR: 1.2, P = 0.001). A greater index CCI score was associated with a greater risk for VTE recurrence, 
Patient Clinical Characteristics of Commercially and Medicare Insured Study Populations
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The number of all-cause and VTE-related outpatient medical service claims, ER claims, and outpatient pharmacy claims were also significantly greater for patients with recurrent VTE. Mean total payments for all health care resource utilization, including inpatient, outpatient medical services, and outpatient pharmacy use were 2. 
Stratified by Index Event (%)
DVT Only PE Only DVT/PE
Index Event
FIGURE 3b
Monthly (Tables 4 and 5 ).
Comparison of Adjusted Total Health Care Payments: Patients with VTE Recurrence Versus Patients Without VTE Recurrence
After adjustment for key patient characteristics among cohorts of the commercially insured population, VTE recurrence was associated with 2.2-fold (P < 0.001) and 3.0-fold (P < 0.001) higher health care payments for all causes and for VTE, respectively, during the 12-month follow-up period (Table 6 ). VTE recurrence was associated with 1.8-fold and 2.1-fold higher health care costs for all causes and for VTE-related claims, respectively, during the 30-day period following the index VTE event ( After adjustment for key patient characteristics among cohorts of the Medicare insured population, VTE recurrence was associated with 1.8-fold (P < 0.001) and 3.4-fold (P < 0.001) higher health care payments for all causes and for VTE, respectively, during the 12-month follow-up period (Table 6 ). VTE recurrence was associated with 1.6-fold and 1.8-fold higher health care costs for all causes and for VTE-related claims, respectively, during the 30-day period following the index VTE event (Table 6 ). Absolute differences in health care payments for patients with VTE recurrence versus those without a VTE recurrence during the 12-month follow-up period were $25,287 (CI: $22,167, $28,407, P < 0.05) and $19,788 (CI: $18,185, $21,390, P < 0.05) for all causes and for VTE-related claims, respectively, and during the 30-day follow-up period were $5,677 (CI: $4,755, $6,599, P < 0.05) and $6,114 (CI: $5,304, $6,925, P < 0.05) for all causes and for VTE-related claims, respectively. These results were similar in the sensitivity regression analysis in which absolute differences in health care payments for patients with VTE recurrence versus those without a VTE recurrence during the 12-month followup period were $26,029 (CI: $14,222, $37,836, P < 0.05) and $18,630 (CI: $13,326, $23,933, P < 0.05) for all causes and for VTE-related claims, respectively, and during the 30-day follow-up period were $5,129 (CI: $1,878, $8,380, P < 0.05) and $5,562 (CI: $2,779, $8,345, P < 0.05) for all causes and for VTErelated claims, respectively.
■■ Discussion
This study shows that despite efforts to reverse the trends of VTE at a national level, 6, 7 recurrence rates are high, resulting in an extensive resource and economic burden to the health care system. Among commercially and Medicare insured patients who experienced an initial VTE event, the Lefebvre et al. (2012) . 15 One explanation for the greater VTE recurrence rates among our study populations is that we included ER visits in our definition of an acute VTE event, which were not included in the Lefebvre et al. study. 15 VTE recurrence rates in the commercial and Medicare populations were similar to the 14.3% rate of hospital readmission for VTE among patients with VTE as a secondary diagnosis reported by Spyropoulos and Lin. 10 Other less recent studies have reported VTE recurrence rates to range between 7.0% and 14.0%. 11 Even in patients who only experienced an initial event with no recurrence, VTE-related care and associated payments (commercial: $15,123 per patient per year; Medicare: $10,399 per patient per year) were substantial. These results are in line with that of Spyropoulos and Lin in which total VTE-related health care costs in 1 year following a single VTE event were between $7,594 and $27,909, depending on whether the VTE event was DVT, PE, or DVT/PE and whether it was for a primary or secondary diagnosis of VTE. 10 Payments for overall health care resource use, including inpatient, outpatient, and outpatient pharmacy claims were markedly higher for patients with VTE recurrence (~2-to 3-fold) in comparison with patients without a VTE recurrence. The mean total health care payment for any reason for commercially insured patients with VTE recurrence was $82,110 annually with 47.0% attributed to VTE-related care. Medicare patients with a recurrent VTE event incurred less costs than those insured commercially, with a mean total payment of $55,982 annually with 43.0% attributed to VTE-related care. Multivariable regression analyses that were conducted to test the validity of the effect of VTE recurrence status on the 30-day and 12-month all-cause and VTE-related health care costs further confirmed that VTE recurrence is associated with a substantial incremental cost burden.
The 12-month incidence rate of VTE recurrence was higher for the commercially insured patients than Medicare insured patients. As the mean age for the commercially insured VTE patients was much younger than Medicare VTE patients, these results seem counterintuitive, as age is a known risk factor for VTE. However, previous studies have reported that VTE recurrence is unrelated to age. 16, 17 In fact, although we found age to be inversely related to the risk of VTE recurrence among commercially insured patients in our analysis, it was not a significant predictor for VTE recurrence in the Medicare study population. Medicare enrollees included in the MarketScan database have employer-sponsored supplemental insurance, and it is plausible that they may have access to better VTE treatment resulting in lower risk of VTE recurrence. Among the Medicare study population, VTE recurrence rate was affected by the U.S. region in which VTE care took place, which demonstrates that, among the Medicare insured population, VTE recurrence rate appears sensitive to variations in the standards of care. Medicare insured patients may also be more adherent to warfarin therapy than commercially insured patients, since they seek medical care more often due to their higher comorbidity burden than younger patients. It is possible that there was a higher prevalence of VTE recurrence cases associated with the use of oral contraceptives in the younger commercially insured female patients. On the other hand, Spencer et al. (2008) did find that older patients were less likely to have unprovoked VTE than younger patients, and unprovoked VTE represents a greater risk for VTE recurrence than provoked VTE. 17 In the absence of further clinical information, we were unable to obtain a complete clinical profile of study patients or to confirm the causes of VTE recurrences. Further research is needed to confirm our study findings and understand the risk profiles for recurrent VTE events in these 2 study populations.
Based on the results of our study, patients initially treated in the inpatient setting had a lower VTE recurrence rate than those treated in the outpatient setting. This may indicate that patients might have received better treatment for VTE in the inpatient setting. This is of concern, since a focus of health care reform is to switch more to outpatient versus inpatient treatment/management. Therefore, it will be important in future studies to further assess the differences and similarities of the standards of care for VTE patients in the outpatient versus inpatient settings.
Limitations
As in all studies using retrospective database claims analyses, there is the potential for bias in this study. We attempted to alleviate some potential bias by comparing patient groups in which both had experienced an initial VTE event. Additionally, we further used multivariable regression analyses that controlled for differences in many patient characteristics to confirm the burden of VTE recurrences. However, there may be other potential confounding variables that were not measured and controlled for in this study, such as bleeding risk. Due to constraints within the databases, we were unable to differentiate between an outpatient office visit for a VTE recurrence and an outpatient office visit for a follow-up to a VTE event; therefore, VTE recurrence was evaluated only in the inpatient or ER setting during the follow-up period. This may have led to an underestimation of VTE recurrence frequency, since VTE is often diagnosed in an outpatient setting (i.e., physician's office). 18 Additionally, to rule out patients who were followed up in the inpatient setting soon after the index VTE diagnosis, patients admitted to the hospital or ER settings within 2 days of the index VTE event were not included in the patient population with VTE recurrence. Also, since we did not evaluate all VTE-related complications, such as thrombocytopenia, pulmonary hypertension, and post-thrombotic syndrome. Therefore, health care resource utilization and associated payments categorized as VTE-related may have been underestimated, although they were captured in the incremental costs of allcause health care utilization and payments. The MarketsScan databases consist of claims submitted by health care providers on behalf of individuals who are beneficiaries, and such claims are subject to possible coding errors, coding for the purpose of rule-out rather than actual disease, and undercoding, either by the health care provider or due to limitations imposed by the database. In addition, the presence of a diagnostic code does not always definitively indicate the presence of a condition, and coding of secondary conditions may be less reliable. Since patients with acute and chronic VTE disease, which may more likely have received a secondary diagnosis code, were not differentiated in this study, the results may or may not be generalized to these subsets of patients with VTE disease, and further study is warranted. Lastly, the MarketScan databases are based on a large convenience sample, and since the sample is not random, it may fail to generalize well to other populations with alternate health care coverage such as Medicaid.
■■ Conclusions
Even with anticoagulant treatment, VTE recurrence ranged from 11.4% to over 15% with the majority of recurrences occurring within 30 days of the initial VTE event. VTE recurrence is associated with substantial health care resource utilization, primarily inpatient care, resulting in high health care costs. Strategies to improve treatment of patients with VTE are needed to lessen the health care and economic burdens of recurrent VTE.
